11,953 results match your criteria Hypopituitarism

Long-term hormonal and imaging outcomes of adjunctive gamma knife radiosurgery in non-functioning pituitary adenomas: a single center experience.

J Neurooncol 2022 May 20. Epub 2022 May 20.

Department of Endocrinology, P.D. Hinduja Hospital and Medical Research Center, Mumbai, 400016, India.

Purpose: Gamma Knife Radiosurgery(GKRS) is an established modality for treatment of non-functioning pituitary adenomas(NFPA). The objective of the study was to assess long-term hormonal and imaging outcomes after adjunctive GKRS in patients with NFPA.

Methods: A retrospective review of records of 109 patients with NFPA, from 1996 to 2020, who received adjunctive GKRS, was performed. Read More

View Article and Full-Text PDF

Infundibular hemangioblastoma resection: Video case report.

Surg Neurol Int 2021 21;12:296. Epub 2021 Jun 21.

Departments of Neurosurgery and Radiology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, United States.

Background: Hemangioblastomas are benign (World Health Organization Grade I), highly vascular neoplasms commonly associated with Von Hippel-Lindau (VHL) disease.[2] The VHL tumor-suppressor gene, located on chromosome 3, is implicated in sporadic cases and cases associated with VHL disease. Hemangioblastomas most commonly arise in the posterior fossa; however, they may also be found supratentorially or within the spinal cord. Read More

View Article and Full-Text PDF

Recommendation to improve the WHO classification of posterior pituitary tumors as a unique entity: evidence from a large case series.

Endocr Connect 2022 May 1. Epub 2022 May 1.

Y Zhao, Huashan Hospital Fudan University, Shanghai, China.

Introduction: Most studies reporting posterior pituitary tumors (PPTs) are small case series or single cases.

Methods: Patients with a histological diagnosis of PPT from January 2010 to December 2021 in a tertiary center were identified. We reported clinical symptoms, endocrine assessments, radiological and pathological features, and surgical outcomes of PPTs. Read More

View Article and Full-Text PDF

Growth hormone (GH) deficiency and GH replacement therapy in patients previously treated for Cushing's disease.

Pituitary 2022 May 13. Epub 2022 May 13.

SEMPR (Endocrine Division), Department of Internal Medicine, Federal University of Parana, Agostinho Leão Junior 285, Curitiba, PR, 80030-110, Brazil.

Several complications associated with active Cushing's disease may persist even years after complete and successful therapeutic remission of hypercortisolism. Growth hormone deficiency (GHD) shares many clinical features seen in patients with Cushing's disease, and its presence after disease remission (GHD-CR) might negatively influence and potentially worsen the systemic complications caused by previous hypercortisolism. GHD-CR is more prevalent in women, and compared to other causes of GHD, patients are younger at the onset of the pituitary disease, at diagnosis of GHD-CR and at start of GH therapy; prevalence of pituitary macroadenomas and visual abnormalities are lower, while prevalence of diabetes, hypertension, low bone mass, fractures, and worst quality of life, are higher. Read More

View Article and Full-Text PDF

Outcome of Endoscopic Transsphenoidal Surgery for Recurrent or Residual Pituitary Adenomas and Comparison to Non-Recurrent or Residual Cohort by Propensity Score Analysis.

Front Endocrinol (Lausanne) 2022 25;13:837025. Epub 2022 Apr 25.

Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.

Objective: To evaluate the long-term outcomes and safety of endoscopic transsphenoidal surgery (ETS) in recurrent and residual pituitary adenomas (rrPAs), as well as the predictors of gross total resection (GTR) and intraoperative CSF leakage. Furthermore, to compare outcomes and complications with non-rrPAs cohort.

Methods: Clinical and radiological characteristics of patients with rrPAs who underwent ETS were collected between 2017 and 2020. Read More

View Article and Full-Text PDF

IgG4-related hypophysitis: a retrospective cohort study.

Acta Neurochir (Wien) 2022 May 7. Epub 2022 May 7.

Department of Endocrinology, University College London Hospitals NHS Foundation Trust, London, UK.

Purpose: IgG4-related hypophysitis (IgG4-RH) is a rare chronic inflammatory condition of the pituitary gland. This study reports the presentation, management and outcomes for patients with histologically proven IgG4-related hypophysitis.

Methods: A prospectively maintained electronic database was searched over a 14-year period from 1 January 2007 to 31 December 2020 at a single academic centre to identify all patients with a histological diagnosis of IgG4-RH. Read More

View Article and Full-Text PDF

Stiff Person-Like Syndrome: An Unusual Presentation of Pituitary Macroadenoma with Panhypopituitarism.

Case Rep Neurol 2022 Jan-Apr;14(1):157-161. Epub 2022 Mar 18.

Department of Endocrinology, Hospital Putrajaya, Putrajaya, Malaysia.

Pituitary adenoma can manifest as pituitary hypofunction, which can cause symptoms of panhypopituitarism. Commonly, symptoms of hormonal deficiencies such as lethargy, weight change, cold intolerance, and sexual dysfunction are reported. Optic chiasmal compression leads to visual field changes and the discovery of the pituitary lesion. Read More

View Article and Full-Text PDF

Growth Hormone Is Beneficial for Induction of Spermatogenesis in Adult Patients With Congenital Combined Pituitary Hormone Deficiency.

Front Endocrinol (Lausanne) 2022 22;13:868047. Epub 2022 Apr 22.

National Health Commission (NHC) Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Background: Gonadotropins are effective in inducing spermatogenesis in patients with congenital combined pituitary hormone deficiency (CCPHD). Data on recombinant human growth hormone(rhGH) adjuvant treatment to improve gonadotropin-induced spermatogenesis are limited.

Design And Setting: This retrospective study included 60 male patients with CCPHD on a relatively large case series in a single center from mainland China. Read More

View Article and Full-Text PDF

Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency.

Eur J Endocrinol 2022 May 16;187(1):27-38. Epub 2022 May 16.

Clinical Drug Development, Novo Nordisk A/S, Søborg, Denmark.

Objective: Growth hormone (GH) replacement therapy in patients with adult growth hormone deficiency (AGHD) is individually titrated due to variable dose-responses among patients. The aim of this study was to provide clinical guidance on dosing and titration of the novel long-acting GH derivative somapacitan based on analyses of somapacitan dose-insulin-like growth factor I (IGF-I) responses in AGHD patients.

Design: Analyses of dosing information, 4364 somapacitan concentration samples and 4880 IGF-I samples from 330 AGHD patients treated with somapacitan in three phase 3 trials. Read More

View Article and Full-Text PDF

Adding T2 weighted images to FAST1 protocol to evaluate the anatomy of the hypothalamic-pituitary region.

Horm Res Paediatr 2022 May 2. Epub 2022 May 2.

Introduction: Ectopic posterior pituitary (EPP) is a malformation of the hypothalamic-pituitary region presented as a spectrum from isolated growth hormone deficiency (GHD) to multiple pituitary hormone deficiencies (MPHD). Our goal was to establish whether the FAST1.2 protocol, which combines FAST1 protocol with 3D-T2DRIVE images, could identify the pituitary stalk (PS) and the regional anatomy more accurately. Read More

View Article and Full-Text PDF

Surgical Outcome and Evaluation of Strategies in the Management of Growth Hormone-Secreting Pituitary Adenomas After Initial Transsphenoidal Pituitary Adenectomy Failure.

Front Endocrinol (Lausanne) 2022 14;13:756855. Epub 2022 Apr 14.

Department of Neurosurgery, Keelung Chang Gung Memorial Hospital of the Chang Gung Medical Foundation, Keelung, Taiwan.

Acromegaly is a systemic disease that requires multidisciplinary treatment to achieve the best clinical outcome. This study aimed to evaluate the outcomes of the endoscopic transsphenoidal approach (TSA) as the primary treatment for somatotroph adenomas and further investigate patients who had suboptimal surgical results. This retrospective study included 83 patients with somatotroph adenomas treated by TSA at our institution from 1999 to 2010. Read More

View Article and Full-Text PDF

Adrenal crisis secondary to Covid-19 vaccination in patient with hypopituitarism.

AACE Clin Case Rep 2022 Apr 25. Epub 2022 Apr 25.

Division of Endocrinology-Diabetes and Metabolism, Saint Barnabas Medical Center, 94 Old Short Hills Road, Livingston 07039, New Jersey.

Background/objective: Adrenal crisis (AC) is an acute life-threatening condition that can occur in patients with primary or secondary adrenal insufficiency who are already on glucocorticoid replacement therapy or can be a first presentation of adrenal insufficiency. Vaccination with Tdap, influenza and pneumococcal vaccine has been reported as a cause of AC. Our objective is to present a case of AC precipitated by COVID-19 mRNA vaccination in patient with hypopituitarism. Read More

View Article and Full-Text PDF

Overview of Congenital Hypopituitarism for the Neonatologist.

Geoanna Bautista

Neoreviews 2022 May;23(5):e300-e310

Department of Pediatrics, Division of Neonatology, University of California, Davis Children's Hospital, Sacramento, CA.

Congenital hypopituitarism is the deficiency in 1 or more hormones produced by the anterior pituitary or released by the posterior pituitary and has an estimated incidence of 1 in 4,000 to 10,000. Due to the critical role the pituitary plays in growth, metabolic, and reproductive processes, early diagnosis is essential to prevent devastating and often preventable outcomes. However, in neonates with congenital hypopituitarism, symptoms are often nonspecific and tend to overlap with other disease processes, making diagnosis extremely challenging in the neonatal period. Read More

View Article and Full-Text PDF

Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma.

BMC Endocr Disord 2022 Apr 26;22(1):110. Epub 2022 Apr 26.

Department of Endocrinology and Metabolism, Jichi Medical University Saitama Medical Center, 1-847, Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan.

Background: This study aimed to evaluate whether hypereosinophilia is a clinical biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma treated with nivolumab plus ipilimumab.

Methods: This was a retrospective cohort study conducted at Jichi Medical University Saitama Medical Center between January 2018 and December 2020. In total, 12 patients with renal cell carcinoma who presented with immune checkpoint inhibitor-induced hypopituitarism were enrolled in this study. Read More

View Article and Full-Text PDF

Treatment of Acquired Hypothalamic Obesity: Now and the Future.

Paul Dimitri

Front Endocrinol (Lausanne) 2022 6;13:846880. Epub 2022 Apr 6.

The Department of Paediatric Endocrinology, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom.

The hypothalamus is the centre of neuroendocrine regulation of energy homeostasis and appetite. Maldevelopment of, or damage to, the key hypothalamic nuclei disrupts the coordinated balance between energy intake and expenditure leading, to rapid and excessive weight gain. Hypothalamic obesity is compounded by a disruption of the hypothalamic-pituitary axis, sleep disruption, visual compromise, and neurological and vascular sequalae. Read More

View Article and Full-Text PDF

Effect of distance from target on hypopituitarism after stereotactic radiosurgery for pituitary adenomas.

J Neurooncol 2022 Apr 24. Epub 2022 Apr 24.

Department of Neurological Surgery, University of Virginia Health System, Charlottesville, VA, USA.

Introduction: Delayed hypopituitarism is the most common complication after stereotactic radiosurgery (SRS) for pituitary adenomas. The aim of this study was to investigate the relationship between the distance from the hypothalamic-pituitary axis to the treatment target and anterior pituitary function preservation after SRS.

Methods: Between 2007 and 2020, consecutive adult patients who underwent single-session SRS for non-functioning or hormone-secreting pituitary adenomas with ≥ 6 months of follow-up were included. Read More

View Article and Full-Text PDF

A Novel Splice-Site Deletion in the Gene Causes Combined Pituitary Hormone Deficiency in Multiple Sudanese Pedigrees.

Genes (Basel) 2022 04 8;13(4). Epub 2022 Apr 8.

Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.

Pathogenic variants within the gene encoding the pituitary-specific transcription factor, POU class 1 homeobox 1 (), are associated with combined pituitary hormone deficiency (CPHD), including growth hormone, prolactin, and thyrotropin stimulating hormone deficiencies. The aim of the study was to identify genetic aetiology in 10 subjects with CPHD from four consanguineous Sudanese families. Medical history, as well as hormonal and radiological information, was obtained from participants' medical records. Read More

View Article and Full-Text PDF

Case Report: A Detailed Phenotypic Description of Patients and Relatives with Combined Central Hypothyroidism and Growth Hormone Deficiency Carrying Mutations.

Genes (Basel) 2022 03 30;13(4). Epub 2022 Mar 30.

Department of Internal Medicine-Endocrinology, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.

In recent years, variants in immunoglobulin superfamily member 1 () have been associated with congenital hypopituitarism. Initially, variants were only reported in patients with central hypothyroidism (CeH) and macroorchidism. Later on, variants were also reported in patients with additional endocrinopathies, sometimes without macroorchidism. Read More

View Article and Full-Text PDF

The side effects of immune checkpoint inhibitor therapy on the endocrine system.

Indian J Med Res 2021 Apr;154(4):559-570

Department of Endocrinology, Diabetes & Metabolism, State University of New York at Buffalo, Buffalo, NY, USA.

Immune checkpoint inhibitors (ICIs) are a relatively newer class of drugs approved for the treatment of malignancies such as melanoma, renal, bladder and lung cancer. Immune-related adverse events (IrAEs) involving the endocrine system are a common side effect of these drugs. The spectrum of endocrine adverse events varies by the drug class. Read More

View Article and Full-Text PDF

[Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].

Beijing Da Xue Xue Bao Yi Xue Ban 2022 Apr;54(2):369-375

Department of Medical Oncolo1. Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China.

Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases SUMMARY Programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) have been widely used in lung cancer treatment, but their immune-related adverse events (irAEs) require intensive attention. Pituitary irAEs, including hypophysitis and hypopituitarism, are commonly induced by cytotoxic T lymphocyte antigen 4 inhibitors, but rarely by PD-1/PD-L1 inhibitors. Isolated adrenocorticotropic hormone(ACTH) deficiency (IAD) is a special subtype of pituitary irAEs, without any other pituitary hormone dysfunction, and with no enlargement of pituitary gland, either. Read More

View Article and Full-Text PDF

Body mass index at diagnosis of a childhood brain tumor; a reflection of hypothalamic-pituitary dysfunction or lifestyle?

Support Care Cancer 2022 Apr 13. Epub 2022 Apr 13.

Department of Pediatric Endocrinology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.

Purpose: Childhood brain tumor survivors (CBTS) are at risk of becoming overweight, which has been shown to be associated with hypothalamic-pituitary (HP) dysfunction during follow-up. Body mass index (BMI) at diagnosis is related to BMI at follow-up. It is uncertain, however, whether aberrant BMI at brain tumor diagnosis reflects early hypothalamic dysfunction or rather reflects genetic and sociodemographic characteristics. Read More

View Article and Full-Text PDF

Camurati-Engelmann Disease Complicated by Hypopituitarism: Management Challenges and Literature Review of Outcomes With Bisphosphonates.

AACE Clin Case Rep 2022 Mar-Apr;8(2):58-64. Epub 2021 Oct 20.

Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Background: Camurati-Engelmann disease (CED) is a rare bone dysplasia characterized by diffuse diaphyseal osteosclerosis. Skull base involvement in CED can result in hypopituitarism but is seldom reported. Our objective was to report a patient with acquired hypopituitarism due to CED and assess the management challenges. Read More

View Article and Full-Text PDF
October 2021

The sellar region as presenting theater for hematologic malignancies-A 17-year single-center experience.

Endocr J 2022 Apr 8. Epub 2022 Apr 8.

Medical Faculty, University of Belgrade, Belgrade, Serbia.

Hematological neoplastic mass lesions of the sellar region are rare. We identified five cases of hematological malignancy with first presentation in the sellar region from our departmental database of 1,405 patients (0.36%) with sellar lesions diagnosed over the 17-year period (2005-2021). Read More

View Article and Full-Text PDF

Sellar xanthogranuloma: A diagnostic challenge.

Surg Neurol Int 2022 4;13:76. Epub 2022 Mar 4.

King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.

Background: Sellar xanthogranulomas are rare intracranial lesions comprising <1% of all sellar lesions. They were described as a separate entity by the World Health Organization in 2000. Because of the paucity of sellar xanthogranuloma cases reported in the literature, they remain a diagnostic challenge with indefinite origin, clinical course, and outcome. Read More

View Article and Full-Text PDF

The role of growth hormone for fertility in women with hypopituitarism.

Growth Horm IGF Res 2022 Apr 29;63:101458. Epub 2022 Mar 29.

Neurosurgery and Medicine (Endocrinology and Metabolism), Stanford University School of Medicine, 300 Pasteur Drive, Grant-S025, Stanford, CA 94305-5103, United States of America.

Growth hormone (GH) is an important regulator of the female reproductive system. In vitro and non-human in vivo studies demonstrate a role of GH in steroidogenesis, folliculogenesis, and post-fertilization development. Given its ability to modulate the reproductive system and potentiate the effects of gonadotropins, a beneficial role of GH replacement therapy to optimize fertility has been suggested. Read More

View Article and Full-Text PDF

Characterization of pituitary stem/progenitor cell populations in spontaneous dwarf rats.

J Vet Med Sci 2022 May 5;84(5):680-688. Epub 2022 Apr 5.

Laboratory of Veterinary Biochemistry, Joint Department of Veterinary Medicine, Faculty of Agriculture, Tottori University, Tottori, Japan.

Spontaneous dwarf rat (SDR) is a primary experimental animal model for the study of pituitary dwarfism with a point mutation in the Gh gene encoding growth hormone (GH). In previous studies, SDR has been reported to be associated with the GH deficiency as well as combined hormone deficiencies, the cause of which is unknown. In this study, we focused on the characteristics of pituitary stem/progenitor cell populations, which are a source of hormone-producing cells, in SDR. Read More

View Article and Full-Text PDF

Pituitary abscess in an eight-year-old girl - diagnostic difficulties.

Endokrynol Pol 2022 5;73(2):379-380. Epub 2022 Apr 5.

Department of Paediatrics with Clinical Assessment Unit, The Medical University of Warsaw, Poland.

Not required for Clinical Vignette. Read More

View Article and Full-Text PDF

Pituitary Stalk Germ Cell Tumors: Retrospective Case Series and Literature Review.

Int J Endocrinol 2022 26;2022:9213220. Epub 2022 Mar 26.

Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.

Objective: Intracranial germ cell tumors with isolated pituitary stalk involvement are rare. Early recognition and long-term monitoring deserve further exploration.

Methods: A retrospective study reviewing eleven intracranial germ cell tumor patients with isolated pituitary stalk involvement was performed. Read More

View Article and Full-Text PDF

Long-term safety of growth hormone in adults with growth hormone deficiency: Overview of 15,809 GH-treated patients.

J Clin Endocrinol Metab 2022 Apr 3. Epub 2022 Apr 3.

Barrow Pituitary Center, Barrow Neurological Institute, University of Arizona College of Medicine and Creighton School of Medicine, Phoenix, AZ, USA.

Context: Data on long-term safety of growth hormone (GH) replacement in adults with GH deficiency (GHD) are needed.

Objective: To evaluate the safety of GH in the full KIMS (Pfizer International Metabolic Database) cohort.

Design, Patients, Setting, And Intervention: The worldwide, observational KIMS study included adults and adolescents with confirmed GHD. Read More

View Article and Full-Text PDF

Reply to Letter: Ways to Improve the Diagnosis of Growth Hormone Deficiency.

David B Allen

Horm Res Paediatr 2022 1;95(1):97-98. Epub 2022 Apr 1.

Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

View Article and Full-Text PDF